The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | The FDA has released an "initial batch" of more than 200 complete response letters (CRLs) in efforts to boost transparency.

The US Food and Drug Administration has started making rejection letters that pharmaceutical companies traditionally keep under wraps more easily available to investors and the public, a move with the potential to reveal serious questions raised about drugs while they were in development.

Complete response letters are issued directly to product sponsors once the FDA finishes all tiers of its review process and concludes that it cannot approve an application in its